Ads
related to: sickle cell disease treatment act- Safety and Side Effects
Review the Safety Profile
And Potential Side Effects.
- Find Treatment Centers
Find an Authorized Treatment Center
By Using the Map Search Feature.
- Mechanism of Action
See How Gene Therapy Works.
Learn the Science Behind Treatment
- HCP Resources
Download Treatment Brochures,
Billing Codes, and More.
- Prescribing Information
View Full Prescribing Information &
Indications And Usage.
- Treatment Journey
Learn More About Treatment And
See If It's Right for Your Patients
- Safety and Side Effects
Search results
Results From The WOW.Com Content Network
Indications for red blood cell transfusion. Transfusion therapy for sickle-cell disease entails the use of red blood cell transfusions in the management of acute cases of sickle cell disease and as a prophylaxis to prevent complications by decreasing the number of red blood cells (RBC) that can sickle by adding normal red blood cells.
It has a safe profile in sickle cell patients and healthy volunteers, without any dose-limiting toxicity. [9] It was developed by Global Blood Therapeutics, a subsidiary of Pfizer. [10] In November 2019, voxelotor received accelerated approval in the United States for the treatment of sickle cell disease for those twelve years of age and older.
Treatment is the same as for patients with sickle cell disease. Patients may receive hydroxyurea to induce the protective effects of increased fetal hemoglobin production. They may also benefit from blood transfusions especially during vaso-occlusive crises.
Lovotibeglogene autotemcel, sold under the brand name Lyfgenia, is a lentiviral gene therapy used for the treatment of sickle cell disease. [1] [3] [4] [5]The most common side effects include stomatitis (mouth sores of the lips, mouth, and throat), low levels of platelets, white blood cells, and red blood cells, and febrile neutropenia (fever and low white blood cell count), consistent with ...
Splenic sequestration crisis is a life-threatening illness common in pediatric patients with homozygous sickle cell disease and beta thalassemia.Up to 30% of these children may develop splenic sequestration crisis with a mortality rate of up to 15%.
Sickle cell disease consists of several subtypes; however, the Haemoglobin type C (HbSC) subtype carries the gravest prognosis for sickle cell retinopathy and vision changes. [ 2 ] Regular retinal examinations can aid in early detection and treatment, thus reducing the impact of the condition and the risk of vision loss.
Ads
related to: sickle cell disease treatment act